

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION N  09/694,088 10/20/2000 Daniel Gaudet 2825.1022-003 7381  Topo 12/18/2001  Doreen M. Hogle, Esq. HAMILTON, BROOK, SMITH & REYNOLDS, P.C. Two Militia Drive Lexington, MA 02421-4799  ART UNIT PAPER NUMBER				• •		
Topo 12/18/2001  Doreen M. Hogle, Esq. HAMILTON, BROOK, SMITH & REYNOLDS, P.C. Two Militia Drive Lexington, MA 02421-4799	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION N	
Doreen M. Hogle, Esq.  HAMILTON, BROOK, SMITH & REYNOLDS, P.C.  Two Militia Drive  Lexington, MA 02421-4799  EXAMINER  NOLAN, PATRICK J	09/694,088	10/20/2000	Daniel Gaudet	2825.1022-003	7381	
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.  Two Militia Drive  Lexington, MA 02421-4799	7	590 12/18/2001				
Two Militia Drive NOLAN, PATRICK J Lexington, MA 02421-4799	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.			EXAMINER		
				NOLAN, PATRICK J		
	Lexington, MA 02421-4799			ARTINIT	PAPED NUMBER	
				DATE MAILED: 12/18/2001		

Please find below and/or attached an Office communication concerning this application or proceeding.





UNITED STATES DEPARTMENT OF COMMERCE Patent and Frademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APP	LICANT	ATTORNEY DOCKET NO.	
		1		EXAMINER	
			ART UNIT	PAPER NUMBER	
			TE MAILED:		

## Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner **Patrick J. Nolan**, Art Unit **1644**, whose telephone number is **703-305-1987**.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

PATRICK J. NOLAN, PH.D.
PRIMARY EXAMINER

12/1/01

Aptication No.: 09/694, 08 8

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

V	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
P	2. Other: Figure 2 has polynucleotide sequences disclosed but no corresponding SEQ ID NOS in the Br Decription of Drawings. If these sequences already have corresponding SEQ ID NOS in the Paper Cop and CRF their insertion into the Specification is required, however if they do not have a correponding SE ID NO, a new CRF and Pape Copy is required.
<b>Ap</b>	plicant Must Provide:
4	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
P	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
W	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216
ror Pat	CRF Submission Help, call (703) 308-4212
ıaı	entIn Software Program Support (SIRA) Technical Assistance703-287-0200
	To Purchase Patentin Software 703 206 2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE